<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179072</url>
  </required_header>
  <id_info>
    <org_study_id>ZS001</org_study_id>
    <nct_id>NCT03179072</nct_id>
  </id_info>
  <brief_title>Dehydr8 and Deactiv8</brief_title>
  <official_title>The Impact of a Typical 8 Day Course of 'Target Weight' Driven Haemodialysis on the Hydration Status, Physical and Cognitive Function, Physical Activity and Quality of Life of Adults With End-stage Renal Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Portsmouth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Portsmouth Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swansea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bangor University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Portsmouth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Managing fluid status is a complex but fundamental part of the clinical care of people
      receiving haemodialysis (HD). Day-to-day fluid management is usually based on the concept of
      'target weight' - the weight used to determine how much fluid should be removed during each
      dialysis session. However, the focus of this approach is usually on avoiding fluid overload
      (hypervolaemia), since this is associated with a higher incidence of cardiovascular and
      pulmonary events, in addition to increased morbidity and morbidity. As a consequence, a
      significant proportion of people on maintenance HD spend a great deal of time in a dehydrated
      state. Although dehydration is known to be associated with a number of unwanted consequences
      (e.g. headaches, severe fatigue, impaired cognitive and physiological function), there has
      been little research focusing on the impact dehydration has on the physical and psychosocial
      well-being of this patient group. Considering the short life expectancy of individuals with
      end-stage renal disease (ESRD) reliant on maintenance HD, particularly those who are unable
      to receive a renal transplant, we should be focused on improving their function and quality
      of life (QoL).

      Key issues that need addressing prior to developing interventions in this cohort are 1)
      investigating the best and alternative measures to assess hydration status and 2) documenting
      the biopsychosocial impact of typical target weight driven HD in a well-designed study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End-stage renal disease (ESRD) represents the final common pathway for all progressive renal
      disease. As of December 2014, 58,968 people in the UK were receiving renal replacement
      therapy (RRT), of which almost half were receiving maintenance haemodialysis (HD; UK Renal
      Registry Report (2014)). The Wessex Kidney Centre cares for ~1,600 patients receiving RRT, of
      which &gt;700 receive HD. The median age of our cohort is 66.7 years, similar to that of all
      incident UK-based patients in 2014 (64.5 years). The RRT recipient population is however
      growing and, increasingly, patients are more elderly with comorbidities. These individuals
      are unlikely to receive transplantation and will therefore depend on dialysis indefinitely.
      Optimising their quality of life (QoL) should be a priority.

      Currently, a standard HD prescription includes a specific volume of ultrafiltration, set to
      achieve a clinically derived estimate of 'target weight'. Acutely, hypervolaemia (fluid
      overload) can be life threatening, whilst chronically it is associated with hypertension and
      an increased cardiovascular risk. Accordingly, target weight is typically prescribed to allow
      for interdialytic weight gains. The sequential reduction of target weight to achieve the
      lowest possible target weight (dry weight probing), thought to improve blood pressure (BP)
      control, left ventricular mass index and long-term outcomes, is favoured by many
      nephrologists. However, this results in dehydration and is associated with increased
      intradialytic symptoms, including intradialytic hypotension, which itself brings an increased
      risk of cardiac death. Local data from the Wessex Kidney Centre suggests that patients
      experiencing a greater drop in systolic BP pre- to post-dialysis are more likely to
      experience symptomatic hypotension during dialysis. Intradialytic BP variability is also
      detrimental to long-term outcomes. Achieving ideal hydration is therefore important for not
      only reducing symptomatology, but also improving BP control and cardiovascular health in
      these patients. Poor cardiovascular health contributes to the reduced physical function
      characterising this group, which along with physical (in)activity is associated with a poorer
      prognosis in this patient group. Furthermore, increased rates of depression and
      cardiovascular disease have been associated with poor physical function in this group.

      There is, however, little research documenting how dehydration impacts individuals undergoing
      dialysis. Specifically, few studies have assessed the link between (de)hydration and frailty,
      although better physical function has been associated with a higher pre-dialysis BP, which
      may simply reflect better hydration. Experience from the Wessex Kidney Centre suggests that
      dehydrated dialysis patients suffer from increasing intradialytic symptomatology and a
      prolonged dialysis recovery time, during which they complain of prolonged fatigue. However,
      no studies have documented whether improving the hydration of dialysis patients improves not
      only their intra- and interdialytic symptomatology, but also their physiological/cognitive
      function, fatigue, physical (in)activity and, ultimately, QoL. Establishing the relationships
      between dehydration and these outcomes is essential, since hydration status can be easily and
      rapidly adjusted. One reason there is limited research in this area is that hydration status
      of individuals undergoing dialysis is difficult to objectively assess, which itself warrants
      further investigation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HHYDRATION STATUS - Change in saliva osmolality following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in saliva osmolality (BIA), sit-to-stand changes in heart rate, thirst perception scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hydration status - Change in plasma osmolality following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in plasma osmolality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hydration status - Change in bioelectrical impedance analysis following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in bioelectrical impedance analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hydration status - change in saliva flow rate following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in saliva flow rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thirst perception - Change in thirst perception following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in simple rating on visual analogue scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in muscular endurance (heel rises)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in muscular endurance (30-seconds sit-to-stand)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in muscular endurance (toe lifts)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in fine motor skills (Moberg's picking-up test)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - Change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in muscle strength (handgrip strength)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - change in physical function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in endurance and walking capacity in patients capable of doing so (6 minute walk test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function - change in cognitive function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in cognitive function - KDQoL Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function - change in cognitive function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), pre-dialysis (day 3), pre-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in cognitive function - EQ-5D-5L Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function - change in cognitive function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Post-dialysis (day 1), similar time of day (day 2), post-dialysis (day 3), similar time of day (day 4), post-dialysis (day 5), similar time of day (day 6), similar time of day (day 7), post-dialysis (day 8)</time_frame>
    <description>Change from baseline in cognitive function - EQ-5D-5L Questionnaire (part 2 repeated only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Activity following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Continuous for 8 day period</time_frame>
    <description>Accelerometry (hip mounted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Activity - change in physical activity across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), pre-dialysis (day 8)</time_frame>
    <description>Change from baseline in physical activity - Rapid Assessment of Physical Activity (RAPA) Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep quality following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Continuous during 8 days (sleep diary each morning)</time_frame>
    <description>Accelerometry / sleep diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of acceptability</measure>
    <time_frame>Following involvement with the study (within 1 week)</time_frame>
    <description>Semi-structured interviews will be used to examine the acceptability of alternative markers of hydration status. Specifically, interviews will explore research methods, and physical and cognitive function, PA, and QoL. Approximately 15-20 semi-structured interviews will be necessary to reach a point of data saturation where no new information is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic function - change in haemodynamic function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic function - change in haemodynamic function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Change in ScvO2 - measured in those who dialyse through a central venous catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic function - change in haemodynamic function following a single session of haemodialysis (short-term) and across typical 8 days of treatment (longer-term)</measure>
    <time_frame>Baseline (day 1: pre-dialysis 1), post-dialysis 1 (day 1), pre-dialysis (day 3), post-dialysis (day 3), pre-dialysis (day 5), post-dialysis (day 5), pre-dialysis (day 8), post-dialysis (day 8)</time_frame>
    <description>Changes in resting heart rate</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>End Stage Renal Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with end-stage renal disease receiving in-hospital haemodialysis at the Wessex
        Kidney Centre will be invited to participate. This centre cares for ~700 HD patients, of
        which ~120 receive in-hospital HD three times a week. As more males have ESRD, it is likely
        that we will have a higher proportion of males. Participant's clinical records will remain
        at the hospital as usual.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The participant must meet ALL of the following criteria to be considered eligible for the
        study:

          -  Male or female &gt; 18 years of age with ESRD and on maintenance HD for &gt; 3 months

          -  Haemoglobin &gt; 10 mg/dL

          -  Participant is willing and able to give informed consent for participation in the
             study

          -  Participant can understand and cooperate with the study protocol

        Exclusion Criteria:

        The participant may not enter the study if ANY of the following criteria apply:

          -  Haemoglobin â‰¤ 10 mg/dL

          -  Unable to understand or cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zoe L Saynor, PhD</last_name>
    <phone>02392 84</phone>
    <phone_ext>3080</phone_ext>
    <email>zoe.saynor@port.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anthony I Shepherd, PhD</last_name>
    <phone>02392 84</phone>
    <phone_ext>5289</phone_ext>
    <email>ant.shepherd@port.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe L Saynor, PhD</last_name>
      <phone>02392843080</phone>
      <phone_ext>3080</phone_ext>
      <email>zoe.saynor@port.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Anthony I Shepherd, PhD</last_name>
      <phone>02392845289</phone>
      <phone_ext>5289</phone_ext>
      <email>ant.shepherd@port.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD, until all avenues of further funding have been exhausted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

